SCHEMBL514182

SCHEMBL514182

[CH2]Sc1ccccc1SC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KMT2A Q03164 4/20 0.35
KDM4E B2RXH2 3/20 0.35
LMNA P02545 3/20 0.35
RXFP1 Q9HBX9 2/20 0.35
MEN1 O00255 2/20 0.35
IDO1 P14902 1/20 0.35
CHRM2 P08172 1/20 0.35
MAPT P10636 2/20 0.34
RAB9A P51151 2/20 0.34
NISCH Q9Y2I1 1/20 0.34
HPGD P15428 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
POLB P06746 2/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL812717 0.85 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA
Ammonia Solution, Strong SCHEMBL16781743 0.82 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA
SCHEMBL28443362 0.77 POLB (0.41) ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA
SCHEMBL2986829 0.77 KMT2A (0.46) ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA
SCHEMBL95282 0.72
SCHEMBL14846126 0.72 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA
SCHEMBL1145440 0.72
SCHEMBL18663864 0.72 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA
SCHEMBL14259069 0.72 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA
SCHEMBL5890646 0.71 KDM4E (0.52) ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5721350-A Deuterated nucleosides CHATTOPADHYAYA JYOTI (SE) 1998-02-24 US claimed
WO-1993025566-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA JYOTI (SE) 1993-12-23 WO claimed
US-20240018180-A1 OLIGONUCLEOTIDE PRODUCTION METHOD AJINOMOTO CO., INC. (JP) 2024-01-18 US disclosed
EP-4293035-A1 OLIGONUCLEOTIDE PRODUCTION METHOD AJINOMOTO CO., INC. (JP) 2023-12-20 EP disclosed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
US-9273149-B2 Methods and compositions for determining the purity of chemically synthesized nucleic acids VERI-Q, INC. (US) 2016-03-01 US disclosed
EP-2276775-B1 PROCESS FOR THE MANUFACTURE OF OLIGONUCLEOTIDES NITTO DENKO AVECIA INC (US) 2015-09-02 EP disclosed
WO-2014184070-A1 MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES SYNGENTA LIMITED (GB) 2014-11-20 WO disclosed
WO-2014184071-A1 MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES SYNGENTA LIMITED (GB) 2014-11-20 WO disclosed
US-20140193855-A1 METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS VERI-Q, INC. (US) 2014-07-10 US disclosed
US-8697355-B2 Methods and compositions for determining the purity of chemically synthesized nucleic acids NORTH CAROLINA STATE UNIVERSITY (US) 2014-04-15 US disclosed
EP-1412752-A1 METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF AND PURIFYING CHEMICALLY SYNTHESIZED NUCLEIC ACIDS VERI-Q, Inc. (US) 2004-04-28 EP disclosed
US-20030044831-A1 Antibody for use in the generation and protection of preferential nucleotide sequences AGRIS PAUL F (US) 2003-03-06 US disclosed
WO-2003003014-A1 METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF AND PURIFYING CHEMICALLY SYNTHESIZED NUCLEIC ACIDS VERI-Q, INC. (US) 2003-01-09 WO disclosed
EP-1242459-A1 METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS NORTH CAROLINA STATE UNIVERSITY (US) 2002-09-25 EP disclosed
US-20020051994-A1 Synthesis of oligonucleotides KWIATKOWSKI MAREK (SE) 2002-05-02 US disclosed
US-20020045167-A1 Used for detecting incomplete deprotection of a synthetic oligonucleotide by immunoassay VERI-Q, INC. 2002-04-18 US disclosed
US-6313284-B1 Solid phase synthesis MAREK KWIATKOWSKI (SE) 2001-11-06 US disclosed
WO-2001049745-A9 METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS UNIV NORTH CAROLINA STATE (US) 2001-09-20 WO disclosed
WO-2001049745-A1 METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS NORTH CAROLINA STATE UNIVERSITY (US) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020051994-A1 Synthesis of oligonucleotides RNGTT, POLR2H, POLR2E ALDH1A1 4690/4885SMN1; SMN2 1547/4885KMT2A 1123/4885
US-20140193855-A1 METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS RNGTT, NOP2, DCLRE1B ALDH1A1 4333/4885SMN1; SMN2 1955/4885KMT2A 2366/4885
US-20030044831-A1 Antibody for use in the generation and protection of preferential nucleotide sequences CD2BP2, IGSF11, RNGTT ALDH1A1 4659/4885SMN1; SMN2 2424/4885KMT2A 2667/4885
US-20240018180-A1 OLIGONUCLEOTIDE PRODUCTION METHOD RNGTT, NOX4, POLRMT ALDH1A1 1227/4885SMN1; SMN2 1937/4885KMT2A 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.